{"id":791840,"date":"2024-12-03T07:40:09","date_gmt":"2024-12-03T12:40:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/"},"modified":"2024-12-03T07:40:09","modified_gmt":"2024-12-03T12:40:09","slug":"pacira-awarded-new-u-s-patent-covering-exparel-composition","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/","title":{"rendered":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8212; First in new family of EXPAREL patents\u00a0&#8212;<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8212; Expands EXPAREL intellectual property and provides protection into 2044 &#8212;<\/em>\n      <\/p>\n<p>PARSIPPANY, N.J., Dec.  03, 2024  (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the \u2018940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The \u2018940 patent, entitled \u201cManufacturing of Bupivacaine Multivesicular Liposomes\u201d protects the chemical composition of EXPAREL<sup>\u00ae<\/sup> (bupivacaine liposome injectable suspension). This patent is the first patent from a new family of patents related to EXPAREL produced by the company\u2019s enhanced large-scale manufacturing process in San Diego, which received approval from the U.S. Food and Drug Administration in February 2024. The company expects the \u2018940 patent to provide protection into July 2044.<\/p>\n<p>\u201cThis new patent highlights our commitment to building a broad portfolio of intellectual property to protect our EXPAREL franchise by expanding its patent life into 2044,\u201d said Frank D. Lee, chief executive officer of Pacira BioSciences. \u201cThis patent, the first of a new family of patents, underscores Pacira\u2019s deep manufacturing expertise and the team\u2019s commitment to innovation. We firmly believe we have a strong portfolio of intellectual property and the EXPAREL franchise is well protected on multiple levels.\u201d<\/p>\n<p>Pacira will submit the \u2018940 patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Patents that are eligible for Orange Book listing are those that have claims covering the active ingredient, the drug product (formulation and composition) or the approved method of use. The company continues to prosecute patent applications and anticipates additional patents are forthcoming.<\/p>\n<p>\n        <strong>Commitment to Protecting EXPAREL Franchise<\/strong>\n      <\/p>\n<p>With the issuance of the \u2018940 patent, the company intends to file a patent infringement lawsuit against Jiangsu Hengrui Pharmaceuticals Co. LTD., and its U.S. distributor, Fresenius Kabi USA, LLC.<\/p>\n<p>A separate lawsuit is advancing against eVenus Pharmaceutical Laboratories, Inc., its China-based parent company, Jiangsu Hengrui, and Fresenius for infringement of U.S. Patent No. 11,819,574 (the \u2018574 patent) in the U.S. District Court for the District of New Jersey. Pacira is also pursuing an appellate review at the Federal Circuit for the New Jersey Court\u2019s finding that the company\u2019s U.S. Patent No. 11,033,495 (the \u2018495 patent) is not valid. To be successful commercially, eVenus, Jiangsu Hengrui, and Fresenius will have to overcome each of Pacira\u2019s patents.<\/p>\n<p>\n        <strong>Expansion of Erucic Acid Family of Patents<\/strong>\n      <\/p>\n<p>The U.S. PTO recently issued U.S. Patent Nos. 12,151,024 (the \u2018024 patent) and 12,144,890 (the \u2018890 patent). The \u2018024 and \u2018890 patents belong to the \u2018574 and \u2018495 family of patents and are listed in the Orange Book with an expiration date of January 21, 2041.<\/p>\n<p>\n        <strong>About Pacira<\/strong>\n      <\/p>\n<p>Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL\u00ae (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA\u00ae (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera\u00ba\u00ae, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>\n        <em>Any statements in this press release about Pacira\u2019s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (\u201cNOPAIN\u201d) Act and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the integration of our new chief executive officer; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera\u00b0; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera\u00b0; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera\u00b0 and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera\u00b0 to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera\u00b0; the commercial success of EXPAREL, ZILRETTA and iovera\u00b0; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (\u201cpMVL\u201d) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the ability to successfully integrate any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the \u201cRisk Factors\u201d of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the \u201cSEC\u201d). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTY2ODViMDQtOWNiNC00NjgyLTljMzYtNjNiNzdjZWI2OTIwLTEwMjA0ODQ=\/tiny\/Pacira-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\nSusan Mesco, (973) 451-4030\r\nsusan.mesco@pacira.com\r\nMedia Contact:\r\nSara Marino, (973) 370-5430\r\nsara.marino@pacira.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; First in new family of EXPAREL patents\u00a0&#8212; &#8212; Expands EXPAREL intellectual property and provides protection into 2044 &#8212; PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the \u2018940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The \u2018940 patent, entitled \u201cManufacturing of Bupivacaine Multivesicular Liposomes\u201d protects the chemical composition of EXPAREL\u00ae (bupivacaine liposome injectable suspension). This patent is the first patent from a new family of patents related to EXPAREL produced by the company\u2019s enhanced large-scale manufacturing process in San Diego, which received approval from the U.S. Food and Drug Administration &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pacira Awarded New U.S. Patent Covering EXPAREL Composition&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791840","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; First in new family of EXPAREL patents\u00a0&#8212; &#8212; Expands EXPAREL intellectual property and provides protection into 2044 &#8212; PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the \u2018940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The \u2018940 patent, entitled \u201cManufacturing of Bupivacaine Multivesicular Liposomes\u201d protects the chemical composition of EXPAREL\u00ae (bupivacaine liposome injectable suspension). This patent is the first patent from a new family of patents related to EXPAREL produced by the company\u2019s enhanced large-scale manufacturing process in San Diego, which received approval from the U.S. Food and Drug Administration &hellip; Continue reading &quot;Pacira Awarded New U.S. Patent Covering EXPAREL Composition&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T12:40:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pacira Awarded New U.S. Patent Covering EXPAREL Composition\",\"datePublished\":\"2024-12-03T12:40:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/\"},\"wordCount\":1236,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/\",\"name\":\"Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\",\"datePublished\":\"2024-12-03T12:40:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-awarded-new-u-s-patent-covering-exparel-composition\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pacira Awarded New U.S. Patent Covering EXPAREL Composition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/","og_locale":"en_US","og_type":"article","og_title":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk","og_description":"&#8212; First in new family of EXPAREL patents\u00a0&#8212; &#8212; Expands EXPAREL intellectual property and provides protection into 2044 &#8212; PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the \u2018940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The \u2018940 patent, entitled \u201cManufacturing of Bupivacaine Multivesicular Liposomes\u201d protects the chemical composition of EXPAREL\u00ae (bupivacaine liposome injectable suspension). This patent is the first patent from a new family of patents related to EXPAREL produced by the company\u2019s enhanced large-scale manufacturing process in San Diego, which received approval from the U.S. Food and Drug Administration &hellip; Continue reading \"Pacira Awarded New U.S. Patent Covering EXPAREL Composition\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-03T12:40:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition","datePublished":"2024-12-03T12:40:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/"},"wordCount":1236,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/","name":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=","datePublished":"2024-12-03T12:40:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjkzMSM2NjE4NDAwIzIwMDg5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-awarded-new-u-s-patent-covering-exparel-composition\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pacira Awarded New U.S. Patent Covering EXPAREL Composition"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791840"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791840\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}